ATE491451T1 - N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz - Google Patents

N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz

Info

Publication number
ATE491451T1
ATE491451T1 AT04793684T AT04793684T ATE491451T1 AT E491451 T1 ATE491451 T1 AT E491451T1 AT 04793684 T AT04793684 T AT 04793684T AT 04793684 T AT04793684 T AT 04793684T AT E491451 T1 ATE491451 T1 AT E491451T1
Authority
AT
Austria
Prior art keywords
treatment
insulin resistance
desoxynojirimycin
adamantane
pentyl
Prior art date
Application number
AT04793684T
Other languages
English (en)
Inventor
Johannes Aerts
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE491451T1 publication Critical patent/ATE491451T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04793684T 2003-10-29 2004-10-29 N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz ATE491451T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078396 2003-10-29
EP04076936 2004-07-06
PCT/NL2004/000760 WO2005039578A2 (en) 2003-10-29 2004-10-29 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof

Publications (1)

Publication Number Publication Date
ATE491451T1 true ATE491451T1 (de) 2011-01-15

Family

ID=34524734

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04793684T ATE491451T1 (de) 2003-10-29 2004-10-29 N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz

Country Status (11)

Country Link
US (1) US7662838B2 (de)
EP (1) EP1680112B1 (de)
JP (1) JP2007509925A (de)
AT (1) ATE491451T1 (de)
AU (1) AU2004283631A1 (de)
CA (1) CA2544086A1 (de)
DE (1) DE602004030604D1 (de)
IL (1) IL175259A0 (de)
PL (1) PL1680112T3 (de)
PT (1) PT1680112E (de)
WO (1) WO2005039578A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
EP2032134B1 (de) 2006-05-09 2015-06-24 Genzyme Corporation Verfahren zur behandlung von krankhafter fettleber durch hemmung der glucosphingolipid-synthese
GB0614098D0 (en) * 2006-07-15 2006-08-23 Mnl Pharma Ltd Immune response variegation with imino sugars
JP2008104399A (ja) * 2006-10-25 2008-05-08 Spirulina Biological Lab Ltd 糖尿病予防食品
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
US20140227371A1 (en) * 2011-07-13 2014-08-14 Alan David Heath Edible composition
KR20150128899A (ko) * 2013-03-15 2015-11-18 유니터 바이롤로지, 엘엘씨 항박테리아 화합물
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504000B2 (ja) 1986-09-02 1996-06-05 日本新薬株式会社 グルコシルモラノリン誘導体
WO1998002161A1 (en) 1996-07-15 1998-01-22 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
BR9902585A (pt) * 1999-02-11 2000-09-26 Claudio Cerqueira Lopes Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
CZ2004564A3 (cs) * 2001-10-15 2005-03-16 Genentech, Inc. Prostředky pro léčení a diagnózu stavů inzulinové rezistence
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
EP3782655A1 (de) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. Verfahren zur behandlung der pompe-krankheit unter verwendung von 1-deoxynojirimycin und derivaten

Also Published As

Publication number Publication date
PT1680112E (pt) 2011-03-24
EP1680112B1 (de) 2010-12-15
CA2544086A1 (en) 2005-05-06
US20070135487A1 (en) 2007-06-14
PL1680112T3 (pl) 2011-05-31
US7662838B2 (en) 2010-02-16
JP2007509925A (ja) 2007-04-19
WO2005039578A2 (en) 2005-05-06
IL175259A0 (en) 2006-09-05
DE602004030604D1 (de) 2011-01-27
WO2005039578A3 (en) 2005-09-29
AU2004283631A1 (en) 2005-05-06
EP1680112A2 (de) 2006-07-19

Similar Documents

Publication Publication Date Title
ATE491451T1 (de) N-(5-adamantane-1-yl-methoxy- pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz
GB0211649D0 (en) Organic compounds
FI3457135T3 (fi) Fabryn taudin hoitovaihtoehtoja
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
JP2012505883A5 (de)
GB0222514D0 (en) Organic compounds
FI3840753T3 (fi) Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
DE602004026578D1 (de) Neue pharmazeutische verwendungen von staurosporin-derivaten
ATE526023T1 (de) Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
JP2009500045A5 (de)
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
DE60302431D1 (de) Methode zur behandlung eines analgesiebedürftigen patienten
TW200616644A (en) Medicine for prevention or treatment of diabetes
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
DE60212349D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines pharmazeutischen mittels zur prävention und behandlung von sexuellen störungen
DE502007006951D1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties